Italian Biotech DNAswitch Secures €500,000 from BioInnovation Institute for Gene Therapy Development
Italian biotech spin‑off DNAswitch, founded in 2024 and based in Padova, secured €500,000 from the BioInnovation Institute’s Catalyst Fund for Italy, marking the first Italian company to receive support from BII’s International Venture Lab. The funding will accelerate its novel gene‑therapy approach for Huntington’s disease, which activates the transcription factor MTF1 to trigger endogenous neuronal defence mechanisms.